Merck KGaA (FRA:MRK) received a €120.00 ($142.86) price objective from investment analysts at UBS in a research report issued to clients and investors on Wednesday, www.boersen-zeitung.de reports. The brokerage presently has a “buy” rating on the healthcare company’s stock. UBS’s price objective suggests a potential upside of 36.58% from the stock’s current price.

Several other research firms have also weighed in on MRK. Kepler Capital Markets set a €115.00 ($136.90) target price on shares of Merck KGaA and gave the company a “buy” rating in a research note on Monday, November 6th. Warburg Research set a €115.00 ($136.90) target price on shares of Merck KGaA and gave the company a “buy” rating in a research note on Thursday, November 9th. Independent Research set a €103.00 ($122.62) target price on shares of Merck KGaA and gave the company a “neutral” rating in a research note on Thursday, November 9th. Berenberg Bank set a €116.00 ($138.10) target price on shares of Merck KGaA and gave the company a “buy” rating in a research note on Thursday, November 9th. Finally, Commerzbank set a €103.00 ($122.62) target price on shares of Merck KGaA and gave the company a “neutral” rating in a research note on Thursday, November 9th. Twelve research analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus price target of €107.81 ($128.34).

Shares of Merck KGaA (FRA:MRK) opened at €87.86 ($104.60) on Wednesday. Merck KGaA has a 12 month low of €87.99 ($104.75) and a 12 month high of €115.00 ($136.90).

WARNING: This report was originally posted by American Banking News and is owned by of American Banking News. If you are reading this report on another domain, it was illegally copied and republished in violation of United States & international trademark and copyright law. The original version of this report can be viewed at https://www.americanbankingnews.com/2017/12/06/merck-kgaa-mrk-given-a-120-00-price-target-at-ubs.html.

Merck KGaA Company Profile

MERCK Kommanditgesellschaft auf Aktien provides products in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat colorectal cancer, head and neck tumors, multiple sclerosis, infertility, growth hormone disorders, cardiovascular disorders, diabetes, and thyroid disorders; diagnostics and prescription drugs for allergen immunotherapy; and biosimilars for oncology and inflammatory disorders.

Analyst Recommendations for Merck KGaA (FRA:MRK)

Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.